Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus
| Autor: | Patrick G, Dean, William J, Lund, Timothy S, Larson, Mikel, Prieto, Scott L, Nyberg, Michael B, Ishitani, Walter K, Kremers, Mark D, Stegall |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Aged 80 and over Graft Rejection Male Sirolimus Wound Healing Dose-Response Relationship Drug Incidence Graft Survival Middle Aged Mycophenolic Acid Kidney Kidney Transplantation Survival Analysis Drug Administration Schedule Tacrolimus Acute Disease Humans Drug Therapy Combination Female Immunosuppressive Agents Aged |
| Zdroj: | Transplantation. 77(10) |
| ISSN: | 0041-1337 |
| Popis: | Sirolimus has been associated with an increased risk of wound-healing complications in several retrospective analyses. The authors compared the rates of wound-healing complications in renal allograft recipients in a prospective, randomized trial of sirolimus-mycophenolate mofetil-prednisone versus tacrolimus-mycophenolate mofetil-prednisone.All patients received antithymocyte globulin induction. In the first phase of the study, patients (n = 77) were included regardless of body mass index (BMI). In the second phase (n = 46 patients), the authors excluded patients with a BMI greater than 32 kg/m2, and the target trough sirolimus level was lowered to 10 to 15 ng/mL (previously 15-20 ng/mL). Multivariate logistic regression analyses were performed to identify predictors of wound complications.Fifty-nine patients received tacrolimus and 64 received sirolimus and were included in subsequent analyses. The incidence of complications was 8% (5 of 59) in the tacrolimus group and 47% (30 of 64) in the sirolimus group (P0.0001). Rates of perigraft fluid collections, superficial wound infections, and incisional herniae were significantly higher in the sirolimus group. Multivariate logistic regression showed only sirolimus (P = 0.0001) and BMI (P = 0.0021) to independently correlate with complications. In the first phase of the study, the wound complication rate in the sirolimus group was 55% (21 of 38 patients). After excluding obese recipients and decreasing the target sirolimus level, the wound complication rate in the sirolimus group was 35% (9 of 26 patients; P = 0.1040).The use of sirolimus-based immunosuppressive regimens leads to a higher incidence of wound-healing complications and will require new approaches to patient selection and management to decrease their incidence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|